TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34343140
Drug: Rehabilitative therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitative therapies such as exercise, respiratory muscle training, assistive devices, and manual therapy and stretching
Study: 35665947
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days amoxicillin 1 g + clarithromycin 500 mg + vonoprazan 20 mg twice per day
Study: 35665947
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days amoxicillin 1 g + clarithromycin 500 mg + PPI (omeprazole or esomeprazole or rabeprazole) 20 mg twice/day
Study: 32871029
Drug: HD-DXM monotherapy
Normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-DXM monotherapy
Study: 32008730
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone 400 mg twice daily
Study: 32471476
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment group
Study: 34235780
Drug: Air mixed
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air mixed with emissions from cooking (PM2.5: 96.1 μg/m3)
Study: 34235780
Drug: Air mixed
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air mixed with emissions from candles (PM2.5: 89.8 μg/m3)
Study: 34235780
Drug: Clean filtered
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clean filtered air (PM2.5: 5.8 μg/m3)
Study: 32965030
Drug: Topical Calendula
Normalized name: CALENDULA
DrugBank: Calendula officinalis whole (DB14315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Calendula officinalis
Study: 32965030
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (Sorbolene: 10% glycerine in cetomacragol cream)
Study: 35870478
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic stewardship measures (Control)
Study: 33249467
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg (or dose-reduced 30 mg)
Study: 36193812
Drug: 250 or
Normalized name: Urso-250 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 or 600 mL m‐2 of cow's milk
Study: 36172955
Drug: Dietitian-led intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietitian-led intervention with motivational interviewing during weekly calls
Study: 33465772
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injections every 4, 6, or 8 weeks for 1 year
Study: 33465772
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of anti-VEGF therapy after 1 year of treatment
Study: 34214881
Drug: Alcohol drinkers
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol drinkers (>0 g/day of alcohol intake)
Study: 34214881
Drug: Non-drinkers (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drinkers (0 g/day of alcohol intake)
Study: 33104258
Drug: Sulfotanshinone sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfotanshinone sodium injection combined with tirofiban (n = 99)
Study: 32828785
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium supplements
Study: 32828785
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium supplements
Study: 32196110
Drug: Intradiscal gelified
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal gelified ethanol injection (Discogel)
Study: 32196110
Drug: Intradiscal combination
Normalized name: CHYMOPAPAIN 2nKatU/ML INTRADISCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal combination of pulsed radiofrequency and gelified ethanol injection (PRF+Discogel)
Study: 36279690
Drug: Intravaginal laser
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal laser therapy (2 courses within 1 month)
Study: 36279690
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid suppositories (3 times/week for 3 months)
Study: 35379314
Drug: Active daily
Normalized name: HOMOSALATE 3 mL in 100 mL / OCTINOXATE 8 mL in 100 mL / OXYBENZONE 2 mL in 100 mL TOPICAL LIQUID [GLAMTOX ACTIVE DAILY MOISTURIZING SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active daily use of Alpha-Stim AID for 8 weeks
Study: 33352495
Drug: Herbal drug
Normalized name: herbal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal drug of Coccinia grandis (500 mg once daily for three months)
Study: 33352495
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for three months)
Study: 32812025
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg), Daclatasvir (60 mg), Ribavirin (1200 mg)
Study: 38451525
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor monotherapy after 3 months of DAPT
Study: 36202933
Drug: Oral eplerenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eplerenone
Study: 36202933
Drug: Half-dose PDT
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose PDT (crossover treatment)
Study: 33986477
Drug: Darbepoetin alpha
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alpha (Darbe) 10 μg/kg IV
Study: 33432167
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin (BNT) injections
Study: 32986235
Drug: Drug-coated balloons
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-coated balloons
Study: 34523382
Drug: Nebulised dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised dexmedetomidine 2 μg/kg (group D)
Study: 34523382
Drug: Nebulised ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised ketamine 2 mg/kg (group K)
Study: 32866050
Drug: 25% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% silver nitrate (AgNO3) solution followed by 5% sodium fluoride (NaF) varnish without fTCP
Study: 32866050
Drug: 25% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% silver nitrate (AgNO3) solution followed by 5% sodium fluoride (NaF) varnish with functionalized tricalcium phosphate (fTCP)
Study: 33296830
Drug: nab-paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel plus gemcitabine (nab-P/G)
Study: 33232476
Drug: Pacritinib 100
Normalized name: pacritinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib 100 mg once per day
Study: 33232476
Drug: Pacritinib 100
Normalized name: pacritinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib 100 mg twice per day
Study: 33232476
Drug: Pacritinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib 200 mg twice per day
Study: 34698889
Drug: Atorvastatin (37.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (37.9% of participants)
Study: 34698889
Drug: High-potency statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency statins (atorvastatin and rosuvastatin)
Study: 34929410
Drug: Seven-day course
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-day course of antibiotics
Study: 34929410
Drug: Fourteen-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourteen-day course of antibiotics
Study: 36153529
Drug: Ensuring the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensuring the availability of influenza vaccine supply
Study: 36153529
Drug: Developing influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developing influenza vaccine awareness
Study: 36153529
Drug: Both ensuring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ensuring influenza vaccine supply and developing influenza vaccine awareness
Study: 35724670
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg plus FDCSL (400/90 mg)
Study: 34821105
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tangeretin orally for 4 weeks
Study: 32951708
Drug: Eugenol nanoemulsion
Normalized name: Eugenol
DrugBank: Eugenol (DB09086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eugenol nanoemulsion gel 4%
Study: 35964610
Drug: Mepolizumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (40 mg for 6–11 years; 100 mg for 12–17 years)
Study: 35768897
Drug: Wrist Position
Normalized name: histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wrist Position Sense Test (WPST) treatment group (n=10)
Study: 32952830
Drug: 400μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400μg sublingual Misoprostol
Study: 36384662
Drug: Evolocumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (140 mg subcutaneous every 2 weeks)
Study: 33742240
Drug: Dexamethasone premedication
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone premedication (8 mg/twice daily for 3 days) followed by tapering dexamethasone (4 mg/daily for 2 days followed by 2 mg/daily for 2 days)
Study: 33742240
Drug: Dexamethasone premedication
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone premedication (8 mg/twice daily for 3 days)
Study: 32367340
Drug: ezetimibe/rosuvastatin 10/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/rosuvastatin 10/5 mg
Study: 35729758
Drug: Ketogenic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic diet (KD) (∼25 g CHO/d)
Study: 35729758
Drug: Carbohydrate diet
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate diet (CHO) (∼285 g CHO/d)
Study: 34112100
Drug: Water-based intimate
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based intimate lubricant gel
Study: 36249225
Drug: Thermometer patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermometer patch (Tucky thermometer) for 3 weeks
Study: 35019120
Drug: Physiologic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic Solution (PS) group
Study: 33321462
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PRESSING panel and response dynamics
Study: 33074769
Drug: Sustained Release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Release (SR) tablets of isradipine composed of 15.0% (wt/wt) HPMC
Study: 33074769
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) tablets of isradipine
Study: 33402409
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg daily or 30 mg daily if patients had dose-reduction criteria)
Study: 33402409
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) using aspirin (100 mg daily) plus clopidogrel (75 mg daily) for 6 months
Study: 35905861
Drug: Control (listing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (listing daily activities)
Study: 34090987
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy (SET) 3× weekly for 6 months
Study: 34090987
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1× weekly health lectures)
Study: 34236915
Drug: Triple antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antithrombotic therapy with clopidogrel
Study: 34236915
Drug: Triple antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antithrombotic therapy with potent P2Y12 inhibitors (ticagrelor or prasugrel)
Study: 32762229
Drug: Fractional ultrapulsed
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional ultrapulsed CO2 laser (group L, n=30)
Study: 34971723
Drug: Midazolam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (30 μg/kg)
Study: 33068444
Drug: Secukinumab low
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab low dose (LD: 75/75/150 mg)
Study: 33068444
Drug: Secukinumab high
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab high dose (HD: 75/150/300 mg)
Study: 33068444
Drug: Secukinumab low
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab low dose (LD)
Study: 33068444
Drug: Secukinumab high
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab high dose (HD)
Study: 33068444
Drug: Etanercept (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (0.8 mg/kg up to a max of 50 mg)
Study: 32243575
Drug: Oral-B iO
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B iO electric toothbrush
Study: 33372745
Drug: Enoxaparin adjusted
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin adjusted to anti‐Xa level of 0.2‐0.5 international units/mL started at less than 24 hours after insertion of central venous catheter
Study: 36268462
Drug: Direct Oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulants (DOACs) - apixaban, edoxaban, rivaroxaban
Study: 36453014
Drug: G-Rup® syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Rup® syrup (30 ml twice daily for 12 weeks)
Study: 34842573
Drug: Selenase (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenase (intravenous selenium) for 5 days
Study: 33891831
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, n = 713
Study: 33891831
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, n = 751
Study: 33592868
Drug: A+HA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: A+HA (20 mL daily for 8 weeks)
Study: 33592868
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL daily for 8 weeks)
Study: 36306168
Drug: AbobotulinumtoxinA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA (2 U/kg for cycle 1 only, 8 U/kg and 16 U/kg) followed by a tailored home exercises therapy programme
Study: 36306168
Drug: AbobotulinumtoxinA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA treatment cycles
Study: 35007482
Drug: Therapist-administered hypnosis
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-administered hypnosis (Group A) for 8 weeks
Study: 32312261
Drug: Ginger extract
Normalized name: ginger extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger extract 500 mg
Study: 36181471
Drug: Liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3.0 mg (or maximum-tolerated dose)
Study: 33531563
Drug: Spaced-learning (2-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaced-learning (2-h weekly sessions over 4 weeks)
Study: 33843297
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity on prescription (n=72)
Study: 34386824
Drug: Open surgical
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open surgical exposure with orthodontic treatment
Study: 34386824
Drug: Closed surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed surgical exposure with orthodontic treatment
Study: 32507132
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) treatment, 12 min/session, three sessions/week for four weeks.
Study: 32507132
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (control group), blinded to participants, for two weeks.
Study: 32331031
Drug: Biofeedback and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback and analgesics
Study: 32331031
Drug: Analgesics alone
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics alone
Study: 35260450
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and angiotensin receptor blockers
Study: 35993376
Drug: Control (prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (prescription drug misuse posts)
Study: 34735908
Drug: RPGE (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPGE (375 mg, 2 tablets, 2 times/day)
Study: 32682074
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI (160/7.2/4.8 μg per actuation) with a 10-second breath-hold
Study: 32682074
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI (160/7.2/4.8 μg per actuation) with a 3-second breath-hold
Study: 32682074
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI (160/7.2/4.8 μg per actuation)
Study: 34497027
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (without currents delivered)
Study: 34999268
Drug: Craving during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craving during treatment
Study: 35473742
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health intervention (informational and testimonial video about opioid tapering + two text messages per day for 28 days)
Study: 34953185
Drug: Ketoprofen lysine
Normalized name: ketoprofen lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen lysine salt solution
Study: 34953185
Drug: Native vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native vitamin D prescriptions
Study: 33307151
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment schedules
Study: 35639365
Drug: Coffee (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (2 cups per day, total amount 160 mg caffeine)
Study: 35639365
Drug: Green Tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Tea (3 cups per day, total amount 252 mg catechin and 96 mg caffeine)
Study: 33596746
Drug: Lactulose 15
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose 15 mL once daily
Study: 33596746
Drug: Sennosides two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sennosides two tablets daily
Study: 32600454
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (Nebido®)
Study: 36266481
Drug: 10-ml 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-ml 0.5% bupivacaine without epinephrine
Study: 36266481
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.9% saline (control)
Study: 32723753
Drug: Gradual antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual antipsychotic reduction and discontinuation
Study: 35868433
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg NVCM intravenously every 12 h and 16 mg NVCM intrathecal administration every 24 h
Study: 35868433
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg NVCM intravenously every 12 h (Control)
Study: 33649919
Drug: Initial use
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial use of oral sodium alginate (arm A)
Study: 33649919
Drug: Late use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late use of oral sodium alginate (arm B)
Study: 32723991
Drug: Two-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-weekly docetaxel for 8 cycles
Study: 35411939
Drug: SOC +
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOC + AAP (Abiraterone acetate 1000 mg + Prednisolone 5 mg)
Study: 35411939
Drug: SOC-alone (Standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC-alone (Standard-of-care androgen deprivation therapy)
Study: 32639561
Drug: BT to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT to Zolpidem (second-stage therapy)
Study: 32639561
Drug: BT to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT to Cognitive Therapy (CT) (second-stage therapy)
Study: 32639561
Drug: Zolpidem to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem to Trazodone (second-stage therapy)
Study: 33161159
Drug: Newly-prescribed medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly-prescribed medical therapy
Study: 33321778
Drug: Co-induction technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-induction technique (4% sevoflurane followed by 0.75 mg/kg propofol)
Study: 33321778
Drug: Sevoflurane (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (8% with 100% oxygen at 8 L/min)